Clinical Trial Detail

NCT ID NCT01953926
Title An Open-label, Phase 2 Study of Neratinib in Patients With Solid Tumors With Somatic Human Epidermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements yes
Sponsors Puma Biotechnology, Inc.
Indications

Advanced Solid Tumor

Therapies

Neratinib

Age Groups: adult senior

Additional content available in CKB BOOST